Related Experiment Video
Updated: Jan 30, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C Garrido-Castro1,2, Nancy U Lin1,2, Kornelia Polyak3,2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract:
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. To date, therapies directed to specific molecular targets have rarely achieved clinically meaningful improvements in outcomes of patients with TNBC, and chemotherapy remains the standard of care. Here, we seek to review the most recent efforts to classify TNBC based on the comprehensive profiling of tumors for cellular composition and molecular features. Technologic advances allow for tumor characterization at ever-increasing depth, generating data that, if integrated with clinical-pathologic features, may help improve risk stratification of patients, guide treatment decisions and surveillance, and help identify new targets for drug development. SIGNIFICANCE: TNBC is characterized by higher rates of relapse, greater metastatic potential, and shorter overall survival compared with other major breast cancer subtypes. The identification of biomarkers that can help guide treatment decisions in TNBC remains a clinically unmet need. Understanding the mechanisms that drive resistance is key to the design of novel therapeutic strategies to help prevent the development of metastatic disease and, ultimately, to improve survival in this patient population.
Insights
Triple-negative breast cancer (TNBC) is difficult to treat. New classification methods using tumor profiling may improve patient risk stratification and guide the development of targeted therapies.
Area of Science:
- Oncology
- Genomics
- Biomarkers
Background:
- Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its aggressive nature and limited targeted treatment options.
- Current standard of care relies heavily on chemotherapy, with molecularly targeted therapies showing minimal clinical benefit.
- TNBC is associated with higher relapse rates, increased metastatic potential, and poorer survival outcomes compared to other breast cancer subtypes.
Purpose of the Study:
- To review recent advancements in classifying triple-negative breast cancer.
- To explore the integration of comprehensive tumor profiling data with clinical-pathologic features.
- To highlight the potential for improved risk stratification, treatment guidance, and novel drug target identification in TNBC.
Main Methods:
- Review of recent scientific literature on TNBC classification and molecular profiling.
- Analysis of technological advancements in tumor characterization.
- Integration of cellular composition and molecular features with clinical-pathologic data.
Main Results:
- Comprehensive tumor profiling offers new avenues for classifying TNBC.
- Integration of detailed tumor data with clinical information can enhance patient risk stratification.
- Emerging data suggests potential for identifying new therapeutic targets and improving treatment strategies.
Conclusions:
- Advanced tumor characterization is crucial for understanding and treating TNBC.
- Biomarker identification remains a critical unmet need for guiding TNBC treatment decisions.
- Understanding resistance mechanisms is key to developing effective novel therapies and improving patient survival.
Related Concept Videos
Molecular Models
Treatment Resistant Cancers
Classification of Elements and Compounds
Compounds are pure substances composed of two or more elements in fixed, definite proportions. Compounds are classified as ionic or molecular (covalent) based on the bonds...
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Negative Regulator Molecules
Positive, Negative, and Zero Work

